[1]徐 军,白 劼.同步放化疗治疗中晚期直肠癌疗效及对肿瘤细胞Bax、Ki-67表达的影响[J].陕西医学杂志,2021,50(5):587-589,602.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.018]
　XU Jun,BAI Jie.Curative effect of concurrent chemoradiotherapy in treatment of rectal cancer and its influence on expression of Bax and Ki-67 in tumor cells[J].,2021,50(5):587-589,602.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.018]
点击复制

同步放化疗治疗中晚期直肠癌疗效及对肿瘤细胞Bax、Ki-67表达的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年5期
页码:
587-589,602
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Curative effect of concurrent chemoradiotherapy in treatment of rectal cancer and its influence on expression of Bax and Ki-67 in tumor cells
作者:
徐 军1; 白 劼2
(1.陕西省核工业二一五医院肿瘤科,陕西 咸阳 712000; 2.榆林市星元医院痔瘘医院一病区,陕西 榆林 719000)
Author(s):
XU Jun; BAI Jie
(Department of Oncology,215 Hospital of Shaanxi Nuclear Industry,Xianyang 712000,China)
关键词:
放化疗;  直肠癌;  细胞凋亡;  Ki-67;  血液毒性反应;  临床疗效
Keywords:
Chemoradiotherapy;  Rectal cancer;  Apoptosis;  Ki-67;  Hematological toxicity;  Clinical efficacy
分类号:
R 735.3
DOI:
DOI:10.3969/j.issn.1000-7377.2021.05.018
文献标志码:
A
摘要:
目的:探讨同步放化疗治疗中晚期直肠癌疗效及对肿瘤细胞Bax、Ki-67表达的影响。方法:选择60例中晚期直肠癌患者作为研究对象,根据随机信封抽签原则把患者分为研究组与对照组各30例。对照组给予化疗治疗,研究组给予同步放化疗治疗,记录随访结果,检测肿瘤细胞Bax、Ki-67表达变化情况。结果:治疗后研究组的总有效率为90.0%,高于对照组的66.7%(P<0.05)。两组治疗期间的血小板减少、粒细胞减少、肝肾功能异常等血液毒性反应对比差异均无统计学意义(均P>0.05)。两组治疗后的促凋亡蛋白Bax表达阳性率高于治疗前(P<0.05),Ki-67表达阳性率低于治疗前(P<0.05)。随访到2021年1月,研究组的中位生存时间与总生存时间均高于对照组(均P<0.05)。结论:同步放化疗治疗中晚期直肠癌患者能促进肿瘤细胞凋亡,抑制Ki-67表达,不会增加血液毒性反应的发生,促进提高治疗效果与延长生存时间。
Abstract:
Objective:To investigate the curative effect of concurrent chemoradiotherapy in the treatment of rectal cancer and its influence on the expression of Bax and Ki-67 in tumor cells.Methods:60 patients with advanced rectal cancer were randomly divided into study group and control group,30 cases in each group.The control group was treated with chemotherapy,while the study group was treated with concurrent chemoradiotherapy.The therapeutic effect was recorded and followed up,the expression changes of Bax and Ki-67 in tumor cells were detected.Results:After treatment,the total effective rate of the study group was 90.0%,which was higher than 66.7% of the control group(P<0.05).There was no statistically significant difference in blood toxic reactions such as thrombocytopenia,neutropenia,liver and kidney dysfunction between the two groups during treatment(all P>0.05).After treatment,the positive rate of pro-apoptotic protein Bax expression in the two groups was higher than that before treatment(P<0.05),and the positive rate of Ki-67 expression in the two groups was lower than that before treatment(P<0.05).Follow up to January 2021,the median survival time and overall survival time of the study group were more than those of the control group(both P<0.05).Conclusion:The application of concurrent chemoradiotherapy in the treatment of patients with rectal cancer can promote tumor cell apoptosis,inhibit Ki-67 expression,and will not increase the occurrence of hematotoxicity,promote the improvement of treatment effect and prolong the survival time.

参考文献/References:

[1] 汪耔璇,李 烜.补中益气汤联合化疗治疗晚期结直肠癌临床研究[J].陕西中医,2020,41(10):1414-1417.
[2] 王向阳,樊 萍,樊橡伟.参丹散结胶囊联合多针扇形交叉立体定位射频消融术治疗老年结直肠癌肝转移临床研究[J].陕西中医,2019,40(8):1001-1005.
[3] 王美玲,卞邦健.卡培他滨术前和术后同步放化疗对中低位直肠癌患者血清TRAIL及DEK水平的影响[J].陕西医学杂志,2019,48(4):502-504.
[4] 高怀军,余 伟.腹腔镜结直肠癌根治术治疗结直肠癌临床疗效及对患者胃肠功能的影响[J].陕西医学杂志,2019,48(8):990-993.
[5] Cienfuegos JA,Rodríguez J,Baixauli J,et al.Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer oncologic outcomes[J].Rev Esp Enferm Dig,2020,112(1):16-22.
[6] Dang Y,Gao H,Huang S,et al.Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer:A case report[J].Mol Clin Oncol,2020,13(2):186-190.
[7] Nakanishi R,Yamaguchi T,Akiyoshi T,et al.Laparoscopic and robotic lateral lymph node dissection for rectal cancer[J].Nat Commun,2020,50(3):209-216.
[8] 沙英娇,武惠韬,温新宇,等.直肠癌新辅助放化疗后病理完全缓解的临床因素研究[J].中华医学杂志,2020,100(11):859-863.
[9] 尹露茜,杨 洁,冯燕茹,等.凋亡通路基因的遗传变异与直肠癌患者术后同步放化疗不良反应有关[J].中华肿瘤杂志,2020,42(5):376-382.
[10] Fokas E,Glynne-Jones R,Appelt A,et al.Outcome measures in multimodal rectal cancer trials[J].Lancet Oncol,2020,21(5):252-264.
[11] Jonsson G,Philipson L,Villman K,et al.Upfront radiotherapy in patients with asymptomatic incurable rectal cancer:A retrospective cohort study[J].Cancer Sci,2020,40(10):5853-5860.
[12] Myint AS,Gerard JP.Role of radiotherapy in the treatment of rectal cancer in older patients[J].Eur J Surg Oncol,2020,46(3):349-357.
[13] 张 杭,孙 戈,郑 阔,等.直肠癌新辅助放化疗后病理完全缓解患者预后的危险因素分析[J].中华胃肠外科杂志,2020,23(3):305-311.
[14] 曹 慧,邹勇斌,唐世强,等.直肠癌同步放化疗期间急性血液学毒性与临床因素及骨盆剂量学参数的相关性分析[J].现代肿瘤医学,2020,28(11):1913-1916.
[15] 温镕博,张 卫.对直肠癌患者新辅助治疗后等待观察策略的思考[J].中华胃肠外科杂志,2020,23(3):230-236.
[16] Oronsky B,Reid T,Larson C,et al.Locally advanced rectal cancer:The past,present,and future[J].Semin Oncol,2020,47(1):85-92.
[17] Petrelli F,Trevisan F,Cabiddu M,et al.Total neoadjuvant therapy in rectal cancer:A systematic review and meta-analysis of treatment outcomes[J].Ann Surg,2020,271(3):440-448.
[18] 刘启志,张 杭,郝立强,等.中低位直肠癌新辅助放化疗后病理完全缓解的影响因素分析[J].中华胃肠外科杂志,2020,23(12):1159-1163.
[19] 陈唯唯,王文玲,王 刚,等.X射线修复交叉互补基因1多态性与直肠癌新辅助放化疗疗效的前瞻性队列研究[J].中华放射医学与防护杂志,2020,40(10):740-745.
[20] Randrian V,Biau J,Benoit C,et al.Preoperative intensity-modulated radiotherapy of rectal cancers:Relevance and modalities[J].Cancer Radiother,2020,24(4):345-353.

相似文献/References:

[1]杜昆利,任佳慧,张雅静,等.全层间断缝合法对回肠造口还纳术后切口愈合的影响[J].陕西医学杂志,2020,49(12):1654.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.031]
　DU Kunli,REN Jiahui,ZHANG Yajing,et al.Effect of full-thickness interrupted suture on wound healing after ileostomy closure[J].,2020,49(5):1654.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.031]

更新日期/Last Update: 2021-05-06